The investigators plan to include 15 patients with insect venom allergy and will collect blood at four time points and stool at three time points during the first week of immunotherapy.
The patients will receive usual standard of care and no intervention. We will, however, include blood draw and stool samples collection from the patients.

The investigators plan to include 15 patients with pollen allergy and will collect blood at five time points and stool at three time points during the first three months of immunotherapy.
The patients will receive usual standard of care and no intervention. We will, however, include blood draw and stool samples collection from the patients.

The investigators plan to include 10 control persons without a clinical history of allergies. Blood and stool samples will be collected at seven/four times respectively.
The patients will receive usual standard of care and no intervention.

Both lymphocytes and stool samples of the patients will be retained.

Allergy

Blood will be drawn by certified personnel according to local regulations. Stool will be collected by the patients after instructions on how to use a stool collection kit.

Blood draw, stool collection.

Centre Hospitalier de Luxembourg

Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy

Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy: Predicting the T Cell Activation Potential in Vivo From Resting T Cells of Patients

This study will allow to predict the T cell activation potential (by evaluating gene expression networks) in vivo before start of immunotherapy for insect venom or pollen allergy meaning that the investigators will be able to predict which patients will profit from standard immunotherapy and which patients will need to receive altered immunotherapy strategies (i.e. higher doses, longer maintenance).
As this is an observational pilot study the investigators define this as outcome measure.

Sebastian Bode, MD

Clinician Scientist

Luxembourg Institute of Health

Integrated Biobank of Luxembourg

Centre Hospitalier du Luxembourg

Itch

The study will take place in two phases. The first phase consists of a meeting of inclusion. During this phase, the principal investigator of the study will verify the inclusion criteria for patients using a questionnaire and an interview. Then, the effects of video on each person will be tested to verify that they well induce itch and measure it using visual analogue scales. This phase will also test the benefit of the relief by scraping and cold.
The second phase will be carried out only if the mental induction of pruritus has been possible in the first session. It involves acquiring the corresponding physiological signals fMRI. It will also be achieved during this phase an anatomical image of the brain of each participant and an image in DTI.
The phases will be carried out in this order in each participant. They will be separated at least one night.

Laurent MISERY

Central Mechanisms of Chronic Pruritus: Functional and Structural Brain Imaging.

The primary endpoint is to highlight fMRI brain areas activated during a mentally induced pruritus in 3 different populations: healthy subjects (no pre-existing pruritus), patients with chronic urticaria (pruritus related to histaminergic pathway), and psoriasis patients (activation pathway pruritus probably PAR2-ergic but to be confirmed by the study).

The secondary outcome is to verify that data collected, once grouped and established in index, form the combination the better able to explain the membership of an individual (individual analysis) to a pathological community or not.

University Hospital, Brest

150 mg bococizumab injected subcutaneously every 2 weeks for a duration of 52 weeks

150 mg placebo injected subcutaneously every 2 weeks for a duration of 52 weeks

150 mg bococizumab injected subcutaneously every 2 weeks for a duration of 52 weeks
Bococizumab: PF-04950615 is a humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), being developed by Pfizer, Inc for the treatment of primary hyperlipidemia and mixed dyslipidemia.

Bococizumab

150 mg placebo injected subcutaneously every 2 weeks for a duration of 52 weeks
Placebo

Placebo

Total

Sex: Female, Male

Race/Ethnicity, Customized

Region of Enrollment

Absolute CD4 T cell

The primary endpoint for the study is the percent change from baseline in fasting LDL-C at week 12.

Change of LDL-C From Baseline to Week 12

The primary endpoint for the study is the percent change from baseline in fasting total Lp(a) at week 12.

Change in Lp(a) From Entry to Week 12

Overall Study

Priscilla Hsue, PI

Dyslipidemia

Cardiovascular Disease

PF-04950615 is a humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), being developed by Pfizer, Inc for the treatment of primary hyperlipidemia and mixed dyslipidemia.

San Francisco General Hospital

Quest Clinical Research

San Francisco Veteran's Affair Medical Center

Bococizumab HIV Evaluation (B-HIVE) Study

Bococizumab HIV Evaluation (B-HIVE) Study: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Bococizumab, a PCSK9 Inhibitor, in HIV-Infected Subjects

urticaria/protease

Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy

Central Mechanisms of Chronic Pruritus: Functional and Structural Brain Imaging.

Bococizumab HIV Evaluation (B-HIVE) Study

La base de dades d’herbes medicinals més completa avalada per la ciència